發(fā)布時間：2018-02-03 16:15

  本文關鍵詞： 人骨肉瘤U-OS細胞 CDK抑制劑 順鉑 細胞增殖 細胞凋亡　出處：《中國矯形外科雜志》2017年01期 　論文類型：期刊論文

【摘要】：[目的]探討CDK抑制劑NSC 649890聯(lián)合順鉑對人骨肉瘤U2-OS細胞抑制作用及可能的機制。[方法]MTT法檢測分別采用50、100、200、400、800 nmol/L的NSC 649890 2、4、6、8、10μg/ml順鉑、50 nmol的NSC649890聯(lián)合2μg/ml順鉑、300nmol的NSC 649890聯(lián)合6μg/ml順鉑培養(yǎng)48 h后細胞增殖情況,金氏q值評價聯(lián)合用藥效應;流式細胞儀、Western blotting檢測分別采用300 nmol/L的NSC 649890、6μg/ml順鉑及二者聯(lián)合培養(yǎng)48 h后細胞凋亡及凋亡通路相關蛋白表達情況,以上實驗均以單純U2-OS細胞作為對照組。[結果]U2-OS細胞經(jīng)不同濃度順鉑、NSC 649890單獨處理48 h后,細胞抑制率隨兩種藥物濃度增加而顯著升高,比較差異均有統(tǒng)計學意義(P0.05)。在聯(lián)合用藥組中,順鉑與NSC 649890聯(lián)合濃度(2μg/ml+50 nmol/L)組兩藥為協(xié)同作用,(6μg/ml+300nmol/L)組兩藥為相加作用。流式細胞儀檢測顯示,順鉑組、NSC 649890組及聯(lián)合組細胞凋亡率顯著高于對照組(P0.05)。Western blotting檢測結果顯示,與對照組相比,順鉑和NSC 649890單獨作用后均可下調Bcl-2蛋白、procaspase-3蛋白的表達水平及上調Bax蛋白的表達水平,差異均有統(tǒng)計學意義(P0.05),而兩者聯(lián)合作用時效果更加顯著(P0.05)。[結論]NSC 649890能增強順鉑對人骨肉瘤U2-OS細胞的抑制作用。
[Abstract]:[Objective] to investigate the inhibitory effect of CDK inhibitor NSC 649890 combined with cisplatin on human osteosarcoma U2-OS cells and its possible mechanism. [Methods] MTT method was used to detect cisplatin 10 渭 g / ml of 50,100,200,400,800 nmol/L NSC (649890 2G / ml). The proliferation of 50 nmol NSC649890 combined with 2 渭 g / ml Cisplatin 300nmol NSC649890 and 6 渭 g / ml Cisplatin for 48 h was observed. Kim's Q value was used to evaluate the effect of combined medication. Western blotting was used to detect NSC 649890 of 300 nmol/L by flow cytometry. 6 渭 g / ml cisplatin and co-cultured with cisplatin and both for 48 h, apoptosis and apoptosis-pathway related protein expression, U2-OS cells were used as control group. [Results: the inhibition rate of U2-OS cells increased significantly with the increase of the concentration of two drugs after 48 hours of treatment with different concentrations of cisplatin or NSC 649890 alone. The difference was statistically significant in the combination group. The synergistic effect of cisplatin and NSC 649890 was observed in 2 渭 g / ml 50 nmol / L group. 6 渭 g / ml 300nmol / L) group was additive. Flow cytometry showed that the cisplatin group was treated with Cisplatin. The rate of apoptosis in NSC 649890 group and combined group was significantly higher than that in control group (P 0.05). Western blotting assay showed that the apoptosis rate was significantly higher than that in control group. Both cisplatin and NSC 649890 could down-regulate the expression of Bcl-2 protein procaspase-3 and up-regulate the expression of Bax protein. The difference was statistically significant (P 0.05), and the effect of combined action was more significant than that of P0.05 (P 0.05). [Conclusion NSC 649890 can enhance the inhibitory effect of cisplatin on human osteosarcoma U2-OS cells.
【作者單位】： 南昌大學第一附屬醫(yī)院骨科;
【基金】：江西省衛(wèi)生廳科技計劃資助項目(編號:20091059),江西省衛(wèi)生廳中醫(yī)藥科研課題(編號:2012A136) 江西省自然基金資助項目(編號:2010JX02603;20132BAB205081)
【分類號】：R738.1
【正文快照】： 骨肉瘤是一種主要發(fā)病人群為青少年的原發(fā)性惡性腫瘤,其強侵襲性常導致患者早期即出現(xiàn)腫瘤細胞遠處轉移。目前應對骨肉瘤的臨床治療主要以化療-手術-化療為主[1-2]。順鉑是骨肉瘤化療的常見藥物之一,但臨床證實骨肉瘤細胞對順鉑易產(chǎn)生耐藥性[3-4]。小分子細胞周期素依賴性蛋白，

本文編號：1487813